Hypertrophic Cardiomyopathy Center of Excellence
Sanger’s hypertrophic cardiomyopathy (HCM) program offers access to innovative HCM care with one of the largest portfolios of HCM research studies and clinical trials.
Recent Highlights
Inaugural members of the American Society of Echocardiography HCM Forum: Two of our physicians were honored to be invited as inaugural members of this forum. The first meeting was held in Washington, DC in June 2023.
Expanding our research footprint: Our center participates in multiple research initiatives that aim to advance HCM care. This past year, we added several new studies that assess the effects of novel therapeutics in both obstructive and non-obstructive HCM (see below for more information).
Advancing education: One of our physicians was elected as faculty for the American College of Cardiology-initiated educational program entitled Advanced Concepts for the Echocardiographer: Hypertrophic Cardiomyopathy.
Innovations
New referral process improves the patient journey: Led by a dedicated referrals nurse, we introduced a new process that involves a preliminary evaluation before consultation to review a patient’s medical records and order appropriate testing and imaging per a HCM-specific protocol. Through this process, we also coordinate visits for new patients with a geneticist and dietician. This streamlines the patient journey, minimizes unnecessary visits and maximizes the time spent with our providers by ensuring the most recent, relevant information is available. This makes initial patient consultations as efficient and clinically effective as possible.
Revised echocardiography imaging protocols for assessing HCM patients: Based on research led by our team, we implemented new protocols that include innovative methods to assess dynamic LVOT obstruction, such as employing goal-directed Valsalva maneuvers and utilizing amyl nitrate. The research engaged multiple national HCM experts and was featured in the Journal of the American Society of Echocardiography.
Awards
-
-
One of two centers in NC and one of 49 recognized nationally as a HCM Center of Excellence by the Hypertrophic Cardiomyopathy Association
Symptomatic HCM patient with difficultto-demonstrate dynamic obstruction. No significant obstruction noted at rest or with traditional Valsalva. However, the patient developed severe LVOT obstruction with inhalation of amyl nitrate.
Hypertrophic Cardiomyopathy Patient Volumes
-
205
New Hypertrophic
Cardiomyopathy Patients
2023
Internal Data, YTD September 2023 Annualized -
870
Total Hypertrophic
Cardiomyopathy Patients
2023
Internal Data, YTD August 2023 Annualized -
28
Patients on Mavacampten
Internal Data, YTD December 2023 -
23
Total Myectomies
Internal Data, YTD December 2023
Hypertrophic Cardiomyopathy Center of Excellence Research and Clinical Trials
An Open-Label Study of CK3773274 for Patients with Symptomatic HCM (FOREST; CY6022; NCT04848506)
A Phase 3, Multi-Center, Randomized, Double Blind Trial to Evaluate Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Cardiomyopathy (MAPLE; CY6032; NCT05767346)
A Phase 3, Multi-Center, Randomized Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (ACACIA; CY6033; NCT06081894)
A Randomized, Double-Blind, Placebo-Controlled, Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (ODYSSEY-HCM; CV027-031; NCT05582395)
MAVA-LTE- Bristol Myers Squibb
Publications and Presentations
Mitchell CC, Frye C, Jankowski M, et al. A Practical Approach to Echocardiographic Imaging in Patients With Hypertrophic Cardiomyopathy. J Am Soc Echocardiogr. 2023;36(9):913- 932. doi:10.1016/j.echo.2023.04.020. PMID: 37160197
Owens AT, Masri A, Abraham TP, et al. Aficamten for DrugRefractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3. J Card Fail. 2023;29(11):1576-1582. doi:10.1016/j. cardfail.2023.07.003. PMID: 37473912
Martinez KA, Bos JM, Baggish AL, et al. Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death. J Am Coll Cardiol. 2023;82(8):661- 670. doi:10.1016/j.jacc.2023.05.059. PMID: 37587576
Moulson N, Petek BJ, Ackerman MJ, et al. Rationale and Design of the ORCCA (Outcomes Registry for Cardiac Conditions in Athletes) Study. J Am Heart Assoc. 2023;12(11):e029052. doi:10.1161/JAHA.122.029052. PMID: 37259981
Corneil H, Liblik K, Varghese SS, et al. Shared DecisionMaking in Athletes Diagnosed With a Cardiovascular Condition: A Scoping Review. Curr Probl Cardiol. 2023;48(10):101815. doi:10.1016/j.cpcardiol.2023.101815. PMID 37211302
“Return-to-Play for Elite Level Athletes with Sudden Cardiac Death Predisposing Heart Conditions.” Martinez K, Bos MJ, Newman DB, Haylett J, Petek, B, Phelan D, Baggish A, Ackerman MJ, Martinez M. Late Breaking Clinical Trial presentation. American College of Cardiology Scientific Sessions March 5th, 2023.
“HCM or Athletic Remodeling: Shrinking the Gray Zone” The Delaware Valley Echo Society Meeting April 27th, 2023. D Phelan.
“Clinical Applications of LV Strain Imaging in the Evaluation of Cardiomyopathies” Basic to Advanced Echocardiography: Island Ultrasound. Mayo Clinic. May 10th, 2023. D Phelan.
“Athletes Heart vs Hypertrophic Cardiomyopathy” Basic to Advanced Echocardiography: Island Ultrasound. Mayo Clinic. May 10th, 2023. D Phelan.
“Hypertrophic Cardiomyopathy, A Guideline Update”. The 29th Annual International Conference of the Australasian Sonographers Association” Brisbane, May 26th, 2023. D Phelan.
“Common Mistakes in Imaging the Athletes Heart: What to Avoid!” American College of Cardiology, Care of the Athletic Heart: From Elite to Enthusiasts, June 9th, 2023. D Phelan.
“More than the Myocardium: The Role of the Mitral Valve in HCM” American Society of Echocardiography, Scientific Sessions, June 25th, 2023. D Phelan.
“Guideline Review: Multimodality CV Imaging in Patients with HCM” American Society of Echocardiography, Scientific Sessions, June 24th, 2023. D Phelan.
American Society of Echocardiography HCM Forum. Panel members, D Phelan, JD Symanski. June 27th
“HCM Medical Workup and Treatment” South Atlantic Cardiology Society. July 14th. D Phelan Moderator.
Leadership
-
Dermot M. Phelan, MD, PhD, FASE, FACC
The Gragg Endowed Chair in Cardiovascular Medicine Medical Director, Hypertrophic Cardiomyopathy Center Medical Director, The Gragg Center for Cardiovascular Performance Medical Director, Cardiovascular Imaging